PACAP as a Potential Biomarker: Alterations of PACAP Levels in Human Physiological and Pathological Conditions

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-35135-3_48
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The change of plasma pituitary adenylate cyclase‐activating polypeptide levels after aneurysmal subarachnoid hemorrhage

  2016cited by this paper
• VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.

  2015cited by this paper
• Plasma pituitary adenylate cyclase-activating polypeptide concentrations and mortality after acute spontaneous basal ganglia hemorrhage.

  2015cited by this paper
• Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine.

  2015cited by this paper
• Migraine and neuropeptides.

  2015cited by this paper
• Pituitary adenylate cyclase‐activating polypeptide deficiency associated with increased platelet count and aggregability in nephrotic syndrome

  2015cited by this paper
• Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.

  2015cited by this paper
• Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples

  2015cited by this paper
• Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38.

  2014cited by this paper
• Pituitary adenylate cyclase-activating polypeptide (PACAP) in fetal cord blood.

  2014cited by this paper
• Innervation pattern of polycystic ovaries in the women.

  2014cited by this paper
• Role of PACAP in migraine headaches.

  2014cited by this paper
• Changes of PACAP level in cerebrospinal fluid and plasma of patients with severe traumatic brain injury.

  2014cited by this paper
• Pituitary adenylate cyclase activating polypeptide and migraine

  2014cited by this paper
• Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity

  2014cited by this paper
• Pituitary adenylate cyclase–activating polypeptide is reduced in Alzheimer disease

  2014cited by this paper
• Applications of blood-based protein biomarker strategies in the study of psychiatric disorders.

  2014cited by this paper
• Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis.

  2013cited by this paper
• Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients

  2013cited by this paper
• Circulating kisspeptin and pituitary adenylate cyclase-activating polypeptide (PACAP) do not correlate with gonadotropin serum levels

  2013cited by this paper
• Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan

  2013cited by this paper
• Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system.

  2012cited by this paper
• Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice

  2012cited by this paper
• PACAP Immunoreactivity in Human Malignant Tumor Samples and Cardiac Diseases

  2012cited by this paper
• Correlation Between Oocyte Number and Follicular Fluid Concentration of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Women After Superovulation Treatment

  2012cited by this paper
• Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis

  2011cited by this paper
• Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor

  2011cited by this paper
• Investigation of pituitary adenylate cyclase activating polypeptide in human gynecological and other biological fluids by using MALDI TOF mass spectrometry.

  2011cited by this paper
• Alterations of pituitary adenylate cyclase-activating polypeptide-like immunoreactivity in the human plasma during pregnancy and after birth

  2010cited by this paper
• Measurement of vasoactive neuropeptides in biological materials: Problems and pitfalls from 30 years of experience and novel future approaches

  2010cited by this paper
• PACAP38 induces migraine-like attacks in patients with migraine without aura.

  2009cited by this paper
• Presence of pituitary adenylate cyclase activating polypeptide-38 in human plasma and milk.

  2009cited by this paper
• Novel stable PACAP analogs with potent activity towards the PAC1 receptor.

  2008cited by this paper
• Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study.

  2007cited by this paper
• Pulmonary and systemic effects of inhaled PACAP38 in healthy male subjects

  2007cited by this paper
• Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans

  2007cited by this paper
• The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers.

  2007cited by this paper
• Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease.

  2006cited by this paper
• Effect of pituitary adenylate cyclase activating polypeptide-38 on sensory neuropeptide release and neurogenic inflammation in rats and mice.

  2006cited by this paper
• The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation.

  2004cited by this paper
• Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.

  2004cited by this paper
• Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells

  2004cited by this paper
• Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment

  2003cited by this paper
• Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation

  2001cited by this paper
• Identification of pituitary adenylate cyclase-activating polypeptide1-38-binding factor in human plasma, as ceruloplasmin.

  1999cited by this paper
• Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis.

  1999cited by this paper
• Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei.

  1995cited by this paper
• Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat.

  1994cited by this paper
• Pituitary Adenylate Cyclase Activating Polypeptide is a Potent Vasodilator in Humans

  1992cited by this paper
• Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells.

  1989cited by this paper

• The hypothalamic effects of PACAP on the hypothalamic-pituitary-gonadal axis in male mice

  2025cites this paper
• Enhancing Stability and Bioavailability of Peptidylglycine Alpha-Amidating Monooxygenase in Circulation for Clinical Use

  2025cites this paper
• Investigation of PACAP38 and PAC1 Receptor Expression in Human Retinoblastoma and the Effect of PACAP38 Administration on Human Y-79 Retinoblastoma Cells

  2024cites this paper
• Role of endocrine PACAP in age-related diseases

  2023cites this paper
• Female reproductive functions of the neuropeptide PACAP

  2022cites this paper
• Decreased Plasma Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Levels are Linked with Disease Severity in Patients with Liver Cirrhosis

  2021cites this paper
• Changes of pituitary adenylate cyclase activating polypeptide (PACAP) level in polytrauma patents in the early post-traumatic period.

  2021cites this paper
• Presence of Systemic Amyloidosis in Mice with Partial Deficiency in Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Aging

  2021cites this paper
• Significance of serum VIP and PACAP in multiple sclerosis: an exploratory case–control study

  2021cites this paper
• The Neuroprotective and Biomarker Potential of PACAP in Human Traumatic Brain Injury

  2020influential citation
• Investigation of pituitary adenylate cyclase activating polypeptide (PACAP) in human amniotic fluid samples.

  2020cites this paper
• Decreased synovial fluid pituitary adenylate cyclase-activating polypeptide (PACAP) levels may reflect disease severity in post-traumatic knee osteoarthritis after anterior cruciate ligament injury.

  2019cites this paper
• Decreased Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Levels Were Linked with Disease Severity of Postmenopausal Osteoporosis

  2019cites this paper
• PACAP deficiency as a model of aging

  2018cites this paper
• Effects of Pituitary Adenylate Cyclase Activating Polypeptide in Human Proximal Tubule Cells Against Gentamicin Toxicity

  2018cites this paper
• Examination of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) as a Potential Biomarker in Heart Failure Patients

  2018cites this paper
• Accelerated pre‐senile systemic amyloidosis in PACAP knockout mice – a protective role of PACAP in age‐related degenerative processes

  2018cites this paper
• Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma

  2016cites this paper